EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF -Mutated Thyroid Cancer in Japan

Makoto Tahara, Naomi Kiyota, Hiroo Imai, Shunji Takahashi, Akihiro Nishiyama, Shingo Tamura, Yasushi Shimizu, Shigenori Kadowaki, Ken-Ichi Ito, Masahiro Toyoshima, Yoshinori Hirashima, Shinji Ueno und 1 weitere

Thyroid® · 14.03.2024

DOI: 10.1089/thy.2023.0547 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Thyroid®, online erschienen am 14.03.2024. Verfasst von Makoto Tahara und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Hauptthemen laut MEDLINE: Benzimidazoles, Carbamates, Sulfonamides, Thyroid Carcinoma, Anaplastic. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzimidazolesCarbamatesSulfonamidesThyroid Carcinoma, AnaplasticThyroid NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsJapanMutationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafVascular Endothelial Growth Factor A

Stichwörter der Autor:innen

BRAFanaplastic thyroid cancerdifferentiated thyroid cancermolecular targeted therapypapillary thyroid cancer

Substanzen

BenzimidazolesbinimetinibBRAF protein, humanCarbamatesencorafenibProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSulfonamidesVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Kobe, Hyogo, Japan.
  • Department of Medical Oncology, Tohoku University Hospital, Sendai, Miyagi, Japan.
  • Department of Medical Oncology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.
  • Department of Medical Oncology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
  • Department of Medical Oncology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Fukuoka, Japan.

Zitieren

APA

Tahara, M., Kiyota, N., Imai, H., Takahashi, S., Nishiyama, A., Tamura, S., Shimizu, Y., Kadowaki, S., Ito, K. I., Toyoshima, M., Hirashima, Y., Ueno, S., & Sugitani, I. (2024). A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF -Mutated Thyroid Cancer in Japan. Thyroid®. https://doi.org/10.1089/thy.2023.0547

Vancouver

Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, et al. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF -Mutated Thyroid Cancer in Japan. Thyroid®. 2024. doi:10.1089/thy.2023.0547

BibTeX
@article{Tahara2024,
  author = {Tahara, Makoto and Kiyota, Naomi and Imai, Hiroo and Takahashi, Shunji and Nishiyama, Akihiro and Tamura, Shingo and Shimizu, Yasushi and Kadowaki, Shigenori and Ito, Ken-Ichi and Toyoshima, Masahiro and Hirashima, Yoshinori and Ueno, Shinji and Sugitani, Iwao},
  title = {A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF -Mutated Thyroid Cancer in Japan},
  journal = {Thyroid®},
  year = {2024},
  doi = {10.1089/thy.2023.0547}
}
Kostenlos starten →